National Reference Laboratory for Control and Monitoring of Antimicrobial Resistance

Laboratory for, Bulgaria

National Reference Laboratory for Control and Monitoring of Antimicrobial Resistance

Laboratory for, Bulgaria
SEARCH FILTERS
Time filter
Source Type

Velinov T.,National Reference Laboratory for Control and Monitoring of Antimicrobial Resistance | Todorova B.,National Reference Laboratory for Control and Monitoring of Antimicrobial Resistance | Petrov M.,National Reference Laboratory for Control and Monitoring of Antimicrobial Resistance | Dimitrova V.,National Reference Laboratory for Control and Monitoring of Antimicrobial Resistance | Kantardjiev T.,National Reference Laboratory for Control and Monitoring of Antimicrobial Resistance
Problems of Infectious and Parasitic Diseases | Year: 2010

Background: Tigecycline is a new injectable glycylcycline antibacterial product with potent activity and broad spectrum against Gram-positive and Gram-negative bacteria currently used for the treatment of complicated skin and skin structure-infections and intra-abdominal infections. We evaluated the in vitro activity of this compound against clinical strains of Gram-positive and Gram-negative species collected from Bulgarian medical centers in the National Reference Laboratory for Control and Monitoring of Antimicrobial Resistance at the NCIPD. Methods: A total of 187 non-duplicate clinical strains from different medical centers were tested for susceptibility by reference broth microdilution methods according to Clinical and Laboratory Standards Institute guidelines and interpretative criteria. Results: All S. aureus strains were inhibited at a tigecycline MIC of £0.5 μg/ml. Among the tested Enterococcus strains the highest tigecycline MIC value was 0.25 μg/ml. Similarly ESBL producing E. coli and K. pneumoniae exhibited uniformly susceptibility to this compound with MIC values reaching 2 μg/ml only for some strains K. pneumoniae. Among the multiple drug resistant A. baumannii strains collected, our assessment indicated MIC 90 value of 2 μg/ml. Conclusion: Tigecycline showed highly potent in vitro activity against all clinical strains tested and appears to be an excellent therapeutic option for serious infections caused by difficult-to-treat microorganisms. The present study did not detect any tigecycline-resistant strains with the exception of a single A. baumannii isolate with MIC value of 8 μg/ml.

Loading National Reference Laboratory for Control and Monitoring of Antimicrobial Resistance collaborators
Loading National Reference Laboratory for Control and Monitoring of Antimicrobial Resistance collaborators